Journal article
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
- Abstract:
-
The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1G710X mutation showed reduced leukemic growth, increased myeloid differe...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, 2.9MB, Terms of use)
-
- Publisher copy:
- 10.1038/s41408-021-00541-0
Authors
Bibliographic Details
- Publisher:
- Springer Nature
- Journal:
- Blood Cancer Journal More from this journal
- Volume:
- 11
- Issue:
- 9
- Article number:
- 157
- Publication date:
- 2021-09-21
- Acceptance date:
- 2021-03-16
- DOI:
- EISSN:
-
2044-5385
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1196140
- Local pid:
-
pubs:1196140
- Deposit date:
-
2021-09-28
Terms of use
- Copyright holder:
- Rahmani et al.
- Copyright date:
- 2021
- Rights statement:
- ©2021 The Author(s). Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record